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Abstract
Background: Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation and
altered keratinocyte differentiation and inflammation and is caused by the interplay of genetic and environmental
factors. Previous studies have revealed that DNA methylation (DNAm) and genetic makers are closely associated
with psoriasis, and strong evidences have shown that DNAm can be controlled by genetic factors, which attracted
us to evaluate the relationship among DNAm, genetic makers, and disease status.
Methods: We utilized the genome-wide methylation data of psoriatic skin (PP, N = 114) and unaffected control skin
(NN, N = 62) tissue samples in our previous study, and we performed whole-genome genotyping with peripheral
blood of the same samples to evaluate the underlying genetic effect on skin DNA methylation. Causal inference
test (CIT) was used to assess whether DNAm regulate genetic variation and gain a better understanding of the
epigenetic basis of psoriasis susceptibility.
Results: We identified 129 SNP-CpG pairs achieving the significant association threshold, which constituted 28
unique methylation quantitative trait loci (MethQTL) and 34 unique CpGs. There are 18 SNPs were associated with
psoriasis at a Bonferoni-corrected P < 0.05, and these 18 SNPs formed 93 SNP-CpG pairs with 17 unique CpG sites.
We found that 11 of 93 SNP-CpG pairs, composed of 5 unique SNPs and 3 CpG sites, presented a methylation-
mediated relationship between SNPs and psoriasis. The 3 CpG sites were located on the body of C1orf106, the
TSS1500 promoter region of DMBX1 and the body of SIK3.
Conclusions: This study revealed that DNAm of some genes can be controlled by genetic factors and also mediate
risk variation for psoriasis in Chinese Han population and provided novel molecular insights into the pathogenesis
of psoriasis.
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Background
Psoriasis is a chronic inflammatory skin disease with a
complex etiology involving genetic risk factors and en-
vironmental triggers. Psoriasis prevalence in Europe and
North America is about 2%, and the prevalence increases
linearly over an individual’s life course, from 0.12% at
age 1 year to 1.2% at age 18 years [1]. Psoriasis may
cause substantial reduction of mental and physical func-
tioning, strongly influencing the patients’ quality of life
[2]. The tremendous health, social, and economic bur-
den combined with lack of successful treatment of this
disease emphasizes the necessity of exploring the genetic
and molecular mechanism of psoriasis etiology.
DNA methylation (DNAm) is a molecular process that
can reversibly modify cytosine residues in human or
other eukaryote organisms. Since the findings that ex-
ogenous methylated DNA can be transcriptionally
* Correspondence: biozhoufs@163.com; ayzxj@vip.sina.com
†Equal contributors
1Institute and Department of Dermatology, The First Affiliated Hospital,
Anhui Medical University, Meishan Road 81, Hefei 230032, Anhui Province,
China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhou et al. Clinical Epigenetics  (2016) 8:131 
DOI 10.1186/s13148-016-0297-z
repressed when transfected into cultured mammalian
cells, DNAm has been closely related with gene regula-
tion. Epigenetics has been found to closely regulate gene
expression; DNAm may affect the binding efficiency of
transcription factors on gene regulatory elements.
Hypermethylation of CpG islands (CGI) in promoter re-
gions have found to cause repression of regulated genes,
while hypomethylation has led to actively transcript gene
expression. On the other hand, several lines of evidences
support the notion that sequence variations profoundly
correlate with DNAm in human tissues and cultured
cells [3], and this will pave the way for the development
of new therapeutic strategies.
The role of DNAm in cancer pathogenesis and some
common immune-related diseases has been extensively
studied [4]. Skin-based analysis revealed hundreds of
methylation loci that contribute to disease onset or pro-
gression [5]. Only a few epigenome-wide methylation pro-
filing in psoriasis patients have been conducted with
relative small sample size [5, 6]. Meanwhile, disease-
associated DNAm differences may arise as a consequence
of the disease or are independently acted upon by the geno-
type. Thus, it is important to find out the exact sites and
their involvement in regulating the function of this disease.
Previously, we had identified 264 differentially methyl-
ated sites (DMSs) that were significantly associated with
psoriasis [7]. However, the underlying mechanisms of how
these methylation markers associated with psoriasis are
not clear. It has been previously hypothesized that DNAm
can potentially mediate the genetic risk in psoriasis. Utiliz-
ing the blood-derived genotype data and skin-derived epi-
genetic data in a total of 114 psoriasis cases and 62
normal controls, we set out to search the methylation
markers that potentially mediate genetic risk for psoriasis.
Results
Identification of methylation quantitative trait loci
We identified 129 SNP-CpG pairs achieving statistically
significant level (Bonferoni correction P value 6.0 × 10−8
= 0.05/829060); 129 SNP-CpG pairs constituted 28
unique SNPs and 34 unique CpGs (Additional file 1:
Table S1). The methylation quantitative trait loci
(MethQTL) CpG probes varied across annotated regions
with 58.8% (20/34) locating on gene body and none lo-
cating on 3′ UTR or intergenic regions (Additional file
2: Figure S1). Compared to the genome distribution, the
MethQTL CpG probes were significantly enriched in
gene body (P = 0.046, Fig. 1a). CpG probes of the gene
body region were more likely to harbor MethQTL than
probes in intergenic and 3′ UTR regions, the first two
most variable regions of the genome. The likelihood of
detecting MethQTL CpGs was not dependent on the
variability of the methylation level when compared with
the global variation of each category (Fig. 1b). We set out
to see whether the positions of MethQTL CpGs influence
the disease severity by comparing the average methylation
level from annotated regions; we found that the methyla-
tion level in promoter and gene body regions was higher in
severe psoriasis patients than in mild. On the contrary, the
average intergenic methylation level was lower in severe
than in mild psoriasis patients (Additional file 1: Table S2).
In-depth analysis of the major histocompatibility complex
region
Interestingly, almost all of MethQTL SNPs spread over a
3-Mb region covering the major histocompatibility com-
plex (MHC) cluster, which has been reported to harbor
several susceptible loci for psoriasis. In order to assess
whether these SNPs are associated with psoriasis, the as-
sociation between 28 MethQTL SNPs and disease status
was tested using an additive genetic effect model. Of
these SNPs, 18 SNPs were significantly associated with
psoriasis at P value <6.0 × 10−8 (Bonferoni correction)
(Additional file 1: Table S3). The most significant signal
comes from rs130079 (P = 1.02 × 10−9), a coding SNP lo-
cated on the 13th exon of CCHCR1, which leads to T→
C substitution and causes Cys to Gly amino acid vari-
ation (Fig. 2a). After retrieving the public Chip-seq data
Fig. 1 DNA methylation pattern of MethQTL CpG sites. a The
distributions of CpG sites based on their locations in RefSeq genes.
“Genome” represents all of the mapped methylation sites (N = 345,753).
“MethQTL” represents MethQTL CpG sites (N = 31) are controlled by
genetic makers. b Standard variation across the whole genome in
terms of the gene context
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Fig. 2 Association and functional annotation of MethQTL SNPs that located in MHC region. a Scatter plot indicates association between MethQTL
SNPs and psoriasis. The most significant disease-associated signal rs130079 and the most significant CIT-tested SNP rs13203895 are highlighted in
vertical lines. b The first part of Fig. 2b reveals Refseq genes in the interrogated region. The next three lines show transcriptional activity, H3K4me3 and
H3K27ac data across several cell lines from Encode project (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK and NHLF). The last five lines show evolutionary
conservation in mammals, including in mouse, sheep, pig, horse, and dog
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of rs130079 region from GM12878 cell line, we found
that rs130079 region was not overlapping with active
regulatory chromatins marked by H3K4me3 and
H3K27Ac (Fig. 2b). The sequences surrounding
rs130079 are highly conservative among multiple species
including human, pig, sheep, horse, and dog, indicating
its potential role in evolution (Fig. 2b).
Establishing epigenetic mediation of genetic risk
Having established 18 SNPs are tightly associated with
psoriasis and CpG sites, we used causal interference test
(CIT), a formal statistical hypothesis test that quantifies
uncertainty in a causal inference pertaining to a mea-
sured factor, which potentially mediates a known causal
association between a locus and disease phenotype, to
evaluate whether these SNPs mediate CpG sites. These
18 SNPs formed 93 SNP-CpG pairs with 17 unique CpG
sites (Additional file 1: Table S4). By performing a CIT
test for 93 SNP-CpG pairs, the SNP effects of 11 pairs
were attenuated after adjusting for methylation (Table 1).
These 11 SNP-CpG pairs were composed of 5 unique
SNPs (rs13203895 in USP8P1, rs2853953 in HLA-C,
rs10484554 nearby WASF5P, rs2245822 nearby HLA-C,
and rs2853952 in HLA-C) and 3 CpG sites (cg04087571
in SIK3, cg09914444 in DMBX1, and cg0683507 in
C1orf106) and presented a methylation-mediated rela-
tionship between SNPs and psoriasis. The cg04087571
(β = −0.13, 95%CI [−0.16–0.11]), located on the body of
SIK3, presented the most significant mediation for
rs13203895 (Fig. 3). After adjusting for cg04087571, the
effect of rs13203895 on psoriasis decreased from −0.49
to −0.26 (Fig. 3d). The rs13203895 was lying 4.1 kb
downstream of HLA-C and was highly conservative
among multiple species (Fig. 2b). The remaining two
CpG sites are located on the body of C1orf106 and the
TSS1500 promoter of DMBX1, respectively. We noticed
that almost all MethQTL SNPs were located around
HLA-C gene, suggesting that they may have important
role similar to HLA-C in the etiology of psoriasis
(Fig. 2b).
Discussion
Psoriasis is an immune-mediated chronic inflammatory
skin disorder that is characterized by abnormal interac-
tions between keratinocytes and immune cells such as
CD4+ T cells, resulting in keratinocyte hyperprolifera-
tion in the epidermis [6]. Evidence clearly suggests that
the methylation of cytosine residue at CpG dinucleotide
contributes to the development of psoriasis [8]. Methyla-
tion changes in naïve CD4+ T cells may affect CD4+ T
cell polarization in psoriasis, indicating that perturbation
of CD4+ T cell methylation may be critical for psoriasis
pathogenesis [6, 9, 10]. DNAm of dermal mesenchymal
stem cells (MSCs) in psoriasis are probably participant
in the pathogenesis and development of psoriasis
through an extraordinarily complex mechanism [11].
Here, we analyzed the blood-derived genotype data and
skin-derived epigenetic data, aimed to search the methy-
lation markers that potentially mediate genetic risk for
psoriasis.
We implemented causal statistical mediation frame-
work to analyze methylome, genotype, and phenotype
data. There are 129 SNP-CpG pairs achieving the signifi-
cant association threshold, which constituted 28 unique
Table 1 Methylation sites mediate genetic risks in psoriasis
Psoriasis associated DMSs SNPs associated with DMSs
Illumina ID* Gene_context Gene
name
P value
(Meth vs.
Pheno)
Beta
difference
SNP Map Nearby
gene
P value
(Geno vs.
Pheno)
Adjusted P
value (Meth
vs. Geno)
Adjusted
independent P
value (Geno vs.
Pheno)
CIT
P†
cg04087571 Body SIK3 1.69E−10 −0.11 rs13203895 31276305 USP8P1 4.80E−08 0.022 0.004 0.022
cg04087571 Body SIK3 1.69E−10 −0.11 rs2853953 31267728 HLA-C 2.77E−08 0.024 0.010 0.024
cg04087571 Body SIK3 1.69E−10 −0.11 rs10484554 31306778 WASF5P 2.54E−08 0.027 0.005 0.027
cg04087571 Body SIK3 1.69E−10 −0.11 rs2245822 31263023 HLA-C 1.83E−08 0.027 0.010 0.027
cg04087571 Body SIK3 1.69E−10 −0.11 rs2853952 31268092 HLA-C 2.54E−08 0.027 0.008 0.027
cg09914444 TSS1500 DMBX1 1.47E−10 −0.11 rs13203895 31276305 USP8P1 4.80E−08 0.034 0.027 0.034
cg09914444 TSS1500 DMBX1 1.47E−10 −0.11 rs2245822 31263023 HLA-C 1.83E−08 0.037 0.037 0.037
cg09914444 TSS1500 DMBX1 1.47E−10 −0.11 rs10484554 31306778 WASF5P 2.54E−08 0.042 0.030 0.042
cg06834507 Body C1orf106 5.00E−12 −0.11 rs13203895 31276305 USP8P1 4.80E−08 0.046 0.005 0.046
cg06834507 Body C1orf106 5.00E−12 −0.11 rs2853953 31267728 HLA-C 2.77E−08 0.047 0.007 0.047
cg09914444 TSS1500 DMBX1 1.47E−10 −0.11 rs2853953 31267728 HLA-C 2.77E−08 0.041 0.047 0.047
Gene name: According to HUGO Gene Nomenclature Committee; Gene_context: Location of the gene associated CpG-site(s) with respect to the gene context
*Illumina ID is arranged by significance rank of CIT test
†CIT P: the maximum of the component P-values for an omnibus test
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MethQTL and 34 unique CpGs. MethQTL CpG probes
varied across annotated regions with more than half lo-
cating on gene body and none locating on 3′ UTR or
intergenic regions. The phenomenon that MethQTL
CpG probes are enriched in gene body can be inter-
preted by the factors that these probes are more likely to
increase the risk for germline or somatic mutations due
to their increased propensity to become mutated [12].
Upon spontaneous hydrolytic deamination, methylated
cytosine turns into thymine. Thymine is harder to be
repaired than uracil, which results from the deamination
of unmethylated cytosine. Indeed, comprehensive ana-
lyses have revealed that high frequent G→T transver-
sion mutations are easily captured in CpG dinucleotide
across the genome [13]. The likelihood of detecting
MethQTL CpGs is not dependent on the variability of
the methylation level when compared with the global
variation of each category. Thus, genetic variations may
profoundly influence DNAm by some undetermined
mechanisms.
Associations between genetic variation with expression
and methylation levels have been identified in several
studies, both local (cis) and distal (trans) associations of
genetic variation are associate with methylation levels [9,
14, 15]. Same to a previous study on epithelial ovarian
cancer, all of the SNPs were trans-MethQTL in the
current study [16], while some studies reported that cis-
MethQTL account for a larger proportion of MethQTL
[17, 18]. This phenomenon can be interpreted by two
reasons. First, our analysis was based on relatively sam-
ple size and the stringent significance threshold (P =
6.0 × 10−8). Further, more information is needed to
evaluate cis-MethQTL when more skin tissues are avail-
able in the future. Second, all trans-MethQTL were lo-
cated at MHC regions, suggesting a strong genetic
control of methylation variance among the studied
population although the biological mechanism was not
well understood. To check whether MethQTL SNPs
regulate expression of cognate genes, we also retrieved
gene expression data from our previous RNA-seq data
set including 20 PP and 20 NN. However, no significant
expression changes were observed for individuals with
different genotypes.
By using CIT test, we identified three putative media-
tors (cg04087571, cg06834507, and cg09914444) for five
MHC variants. Our analysis indicated that cg04087571,
Fig. 3 Genotype-dependent CpGs potentially mediate genetic risk for psoriasis and the relationship among cg04087571, rs10484554, and
psoriasis. a Association between cg04087571 and disease status. b Association between cg04087571 and rs10484554. Red horizontal bars
represent average DNA methylation levels. c Percentage of cases for each rs10484554 genotype. d The coefficient (β) represents the dependence
of psoriasis phenotype (P) on genotype (G) with or without adjustment for DNA methylation level of cg04087571 (M). The bars represent the 95%
confidence interval for the coefficient. e, f Examples of DMSs potentially mediate genetic risk for psoriasis. Density plots of methylation levels by
genotype for two SNP-CpG pairs. Plot lines were colored by different genotypes
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which is associated with salt-inducible kinase 3 (SIK3),
was the most significant mediator for USP8P1. SIK3 is
an AMP-activated protein kinase-related kinase and a
novel energy regulator that modulates cholesterol and
bile acid metabolism by coupling with retinoid metabol-
ism [19]. We also found that cg06834507, residing in the
body of the C1orf106 gene, was a potential mediator of
genetic risk for psoriasis. The function of C1orf106 re-
mains to be elucidated, but the coding variants in this
gene have been associated with inflammatory Crohn’s
disease (CD) [20], which shares clinical and immuno-
logical features with psoriasis [21]. The CpG site
cg09914444 locates on the TSS1500 promoter of
DMBX1; DMBX1 encodes a member of the bicoid sub-
family of homeodomain-containing transcription factors.
The encoded protein acts as a transcription factor and
may play a role in brain and sensory organ development
[22]. It is well known that stressful life events, anxiety,
and depression constitute the major risks of occurrence
and recurrence of psoriasis, aggravating the severity of
this disease and duration of symptoms [23]. On the con-
trary, psoriasis itself also contributes to depression, anx-
iety, and psychological stress. Though how genotypes be
mediated epigenetically is not clear, one hypothesis as-
sumes that DNAm could mediate phenotypic plasticity
in response to a varying environment [24]. In this study,
we suspected that MHC variants might regulate psoriasis
variability in addition to mean disease phenotype by
regulating psoriasis plasticity through DNAm.
Consistent with the findings from rheumatoid arthritis
(RA) [4], almost all of the psoriasis-related MethQTL lo-
cated in the MHC region harbors several susceptibility
loci for psoriasis. We found that 18 SNPs of 28
MethQTL SNPs were associated with psoriasis, the most
significant signal rs130079 located on the 13th exon of
CCHCR1. Interestingly, we did not find strong CpG me-
diation for this most significant disease-associated locus,
indicating that rs130079 has biological function through
a different pathway. The SNP rs130079 was not located
on active chromatin structure marked by H3K4me3 and
H3K27Ac as indicated by retrieving the public Chip-seq
data, suggesting that rs130079 might not be directly in-
volved in regulating gene expression of nearby genes.
The sequences surrounding rs130079 are highly conser-
vative among multiple species including human, mouse,
dog, and chicken, indicating its potential role in evolu-
tion. Importantly, missense polymorphism of rs130079
causes amino acid substitution from Cys to Gly. Even
previous linkage analysis, fine mapping, conditional ana-
lysis, and genome-wide association study (GWAS) iden-
tified the MHC associated with psoriasis and its clinical
subtypes [5, 25–29], we speculated that rs130079 may be
a methylation mediator that regulates the genetic risk of
psoriasis indirectly.
It should be acknowledged that it is not possible to es-
tablish causality on the basis of a pure case-control
study. The limitation of this study is that we do not have
enough samples to conduct a further replication and val-
idation experiment. Our previous published data sets did
not contain both genetic and DNA methylation data [30,
31]; thus, those data sets were not suit for a complete
validation of SNP-CpG pairs identified here. Actually,
we are collecting more skin samples and aim to perform
new project to reveal genetic and epigenetic cross-
talking in future. As discussed above, the fact that
cg04087571 and cg09914444 can potentially connect ex-
ternal environmental factors and psoriasis status encour-
age us to believe they could play roles in disease
etiology. Meanwhile, we should also emphasize that our
findings are based on epidemiological hypothesis. Al-
though all these findings should be validated in another
independent larger sample size population and with
pathogenesis investigation, these markers can be ser-
viced as a starting point for further studies.
Conclusions
This research is one of few first studies to evaluate geno-
types, methylation, and status variables of psoriasis. We
identified several psoriasis-associated MethQTL CpG
sites and SNPs. The MethQTL CpG sites are enriched in
gene body regions and almost all the MethQTL SNPs lo-
cate in the MHC region. We found that CpG sites of
C1orf106, DMBX1, and SIK3 mediate the genetic risk of
psoriasis. These findings through analysis of epigenome-
wide association data provide new insights into the
pathogenesis of psoriasis and represent a promising av-
enue through which to investigate novel therapeutic ap-
proaches for psoriasis.
Methods
Sample preparation
In our previous study, 217 human skin tissue samples in
114 psoriasis cases and 62 normal controls were col-
lected from the Department of Dermatology, the First
Affiliated Hospital, Anhui Medical University, Anhui
Province, China. Three types of tissues were collected,
including 114 psoriatic skin tissues from psoriasis pa-
tients (PP), 41 matched uninvolved psoriatic skin tissues
from psoriasis cases (PN), and 62 unaffected skin tissues
from normal controls (NN). The detailed clinical charac-
teristics and genome-wide methylation experiment had
been described previously [7]. In this study, we only ana-
lyzed methylation data of 114 PP and 62 NN samples,
the blood-derived genotype data from the same patients.
The case and control samples were matched in the best
way for sex and age. No statistic significances were de-
tected (P > 0.01, Table 2).
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Differentially methylated sites identification
The genome methylation level was detected by using
Infinium Human-Methylation450 BeadChips, which
quantitatively measures more than 485,000 methylation
loci. The methylation detection of each sample was de-
scribed in detail in our previous study [7]. In brief, we
performed single probe CPG methylation and psoriasis
association by the non-parametric Wilcoxon rank-sum
test. Probe expression was considered significantly
different between the tested groups at a Bonferoni-
corrected P < 0.05. Statistic analysis was performed with
Illumina Methylation Analyzer (IMA) package in R. A
total of 264 DMSs were significantly associated with
psoriasis in both PP versus PN and PP versus NN com-
parisons [7]. These 264 DMSs were analyzed in current
study.
Genome-wide genotyping and quality control
The genome-wide genotyping analysis was conducted
using Illumina HumanOmni ZhongHua-8 BeadChips
containing more than 890,000 variations. Genotypes of
SNPs were called by Illumina BeadStudio 3.2 software
(Illumina, San Diego, CA, USA). SNPs were excluded if
they had a call rate lower than 90%, minor allele frequency
(MAF) of <1%, and/or significant deviation from Hardy-
Weinberg equilibrium in the controls (P < 1 × 10−7). After
data cleaning and quality control, 829,060 SNPs remained
for the MethQTL analysis.
Technical verification
To further evaluate the quality of the genotype data, we
selected 5 SNPs (rs13203895, rs2853953, rs10484554,
rs2245822, and rs2853952) to be re-genotyped in 96 se-
lected samples from the HumanOmni ZhongHua-8
Table 2 Statistic summary of study subjects
Samples characteristics Cases Controls P
N 114 62
Sex (male/female) 66/48 25/37 0.02
Age
Mean ± sd 37.3 ± 14.4 40.8 ± 14.6 0.12
Range 10.0–76.0 15.0–75.0
BMI
Mean ± sd 22.8 ± 2.9 22.3 ± 2.8 0.24
Range 16.6–32.8 16.8–29.1
PASI
Mean ± sd 4.1 ± 3.1 /
Range 0.6–16.0 /
Fig. 4 Identification of epigenetically mediated genetic risk factors for psoriasis. a Possible relationship between causal factor (G), a possible mediator
(M), and an outcome (Y). Top, the methylation-mediated relationship, in which genotype (G) acts on phenotype (Y) through methylation (M); middle,
the consequential methylation model, in which DNA methylation (M) changes are the consequence of phenotype (Y); bottom, the independent model,
in which the genotype (G) acts on DNA methylation (M) and phenotype (Y) independently. b The four components of the CIT. c Flow diagram and
results for identifying epigenetically mediated genetic risk for psoriasis
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panel by using the direct Sanger sequencing. The con-
cordance rate between the genotypes from Illumina and
Sanger sequencing was 97.6%. We aimed to verify
methylation data of cg04087571, cg09914444, and
cg06834507 by Sequenom Epitype technology as de-
scribed in supplementary materials of our previous study
[7]. But we failed to find proper primers in these three re-
stricted regions. Instead, we evaluated the performance of
Illumina Methylation450 array using Sequenom Epitype
technology by detecting the nine CpGs reported in previ-
ous study [7]. For 24 PP samples from the Illumina array,
we found high consistency between the two platforms,
suggesting high quality of the original data (spearman cor-
relation pho > 0.6, P < 1 × 104, Additional file 1: Table S5).
To further verify our results, we compared the overlapped
differentially methylated sites that were shared by Human-
Methylation27K and 450 K beadarrays from Roberson’s
and our studies, respectively. Among the 456 overlapped
sites, 99.8% (455/456) loci showed the same hyper- or
hypomethylated trend, suggesting high consistency and
excellent data quality (data was not shown here).
Methylation quantitative trait loci analysis
Associations between all 264 differentially methylated
CpG sites and common SNPs (MAF ≥5%) were exam-
ined. Additive genetic effect model was applied in the
MethQTL analyses. To adjust for age and sex, we first
generated residuals of methylation by regression models
adjusted for age and sex. The residuals of methylation
were then used to associate with SNP genotypes. The as-
sociation analysis was performed using Plink 1.07. To
correct for multiple testing, a rigorous Bonferoni correc-
tion was applied (P < 0.05/829,060 = 6.0 × 10−8). In this
study, the cis-MethQTL was defined as being less than
500 kb upstream and downstream from CpG loci, while
the trans-MethQTL was defined as being more than
500 kb from the target CpG loci in the same chromo-
some or on different chromosomes.
Causal inference test
CIT is applicable to data that includes genotype, possible
causal mediator such as DNA methylation, and an out-
come of interest. CIT is used to assess the relationship
between a causal factor (genotype, G), a potential medi-
ator (methylation, M), and an outcome (psoriasis status,
Y). To clarify that methylation acts as a mediator of gen-
etics for psoriasis, the following criteria should be met:
(i) G and Y are associated, (ii) G is associated with M
after adjusting for Y, (iii) M is associated with Y after
adjusting for G, and (iv) G is independent of Y after
adjusting for M. If M is a consequence of Y or independ-
ently controlled by G, there should be no difference in
the effect of G on Y, when conditioning on M. However,
when M mediates the genetic risk for psoriasis (Table 1),
conditioning on M should substantially reduce the effect
of G on Y (Fig. 4). We focus our CIT analyses on the
psoriasis-associated 264 CpG sites and the SNPs with
significant MethQTL SNPs described above and signifi-
cantly associated with psoriasis. The CIT P value is defined
using the intersection-union test framework as the max-
imum of the four component test P values [32]. The signifi-
cant threshold is set as CIT P < 0.05. The test was
performed by causal interference test or “cit” package in R.
Additional files
Additional file 1: Table S1. Psoriasis-associated DMSs that are
controlled by SNPs. Table S2 Disease severity and position of MethQTL
CpGs. Table S3 The association between psoriasis and MethQTL-SNPs in
MHC region. Table S4 The results of SNP-CpG pairs that mediate the
genetic risk of psoriasis. Table S5 Cross validation between Illumina and
Sequenom platform. (DOCX 112 kb)
Additional file 2: Figure S1. Genomic annotation for methylation
probes. Refseq genes annotations were from the University of California,
Santa Cruz (UCSC) hg18 reference genome [National Center for
Biotechnology Information (NCBI) Reference Sequence Database Release
37]. CpG sites located in or near Refseq genes are separated into TSS1500
(1500 bp upstream of the transcription start site), TSS200, 5′ UTR, first
exon, gene body, and 3′ UTR regions. Intergenic probes refer to
methylation sites not mapping to any of the other categories. The
ambiguous regions include sites that fell into two or more different
categories. The promoter region includes methylation sites located in
TSS1500, TSS200, 5′ UTR, and first exon. (DOC 92 kb)
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